The oral administration of a selective Cox-2 inhibitor, 4-[4-cyclohexyl-2-methyloxazol-5-yl]-2-fluorobenzenesulfonamide (JTE-522), could inhibit NMBA-induced tumor formation in the rat esophagus86. The gene discussed is PTGS2; the disease is neoplasm.